Drug Approval | January 18, 2024
Indoco Remedies receives EIR from USFDA for Goa Plant-I
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
The latest upgraded Tele Clinic is Artificial Intelligence (AI) - driven to provide healthcare facilities in far flung areas of the region, where such facilities are either not available or inadequately available
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Subscribe To Our Newsletter & Stay Updated
